Bioventus delivered Q4 revenue growth with strong organic expansion and improved profitability. Net income turned positive year over year and adjusted EBITDA increased significantly, supported by strong demand in Pain Treatments and disciplined cost management.

Bioventus delivered a strong second quarter, with reported revenue of $147.7 million, a 2.4% decline year-over-year due to a prior-year divestiture. However, organic revenue grew by 6.2%, driven by double-digit organic growth in Surgical Solutions and Restorative Therapies. The company significantly improved its net income to $7.5 million from a loss of $25.7 million in the prior year, and non-GAAP EPS increased by 31% to $0.21. Cash from operations also saw a substantial increase of 71% to $25.9 million.

Bioventus reported a first-quarter net loss of $2.6 million, or $0.04 per share, on revenue of $123.9 million. Despite a decline in reported revenue, organic revenue increased by 5.0%. The company reiterated its full-year 2025 financial guidance.

Bioventus achieved a 13.5% increase in revenue for Q4 2024, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company posted an adjusted EBITDA of $28.3 million, up 28.3% year-over-year. Non-GAAP EPS rose to $0.15 from $0.07 in the prior year. Net loss from continuing operations significantly improved to $0.3 million compared to $7.7 million in Q4 2023.

Bioventus reported a 15.0% increase in worldwide revenue to $139.0 million, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company's net loss from continuing operations was $5.4 million, with adjusted EBITDA advancing 8.4% to $23.6 million.

Bioventus reported a 10.3% increase in worldwide revenue, reaching $151.2 million. Organic revenue growth was 13.9%, driven by Pain Treatments and Surgical Solutions. The company raised its full-year 2024 financial guidance, expecting net sales of $557 million to $567 million and adjusted EBITDA of $104 million to $107 million.

Bioventus reported a strong start to the year with an 8.7% increase in worldwide revenue, totaling $129.5 million, and a net loss from continuing operations of $6.0 million, which is an improvement compared to the prior-year period. The company's adjusted EBITDA from continuing operations increased by 33.5% to $22.6 million. Based on this momentum, Bioventus raised its full-year 2024 financial guidance.

Bioventus reported a 7.6% increase in worldwide revenue for the fourth quarter, driven by strong organic growth in Pain Treatments and Surgical Solutions. The company's net loss decreased compared to the prior year, and adjusted EBITDA improved due to revenue growth and cost management. Full-year revenue remained consistent with the previous year, with growth in Surgical Solutions.

Bioventus reported Q3 net sales of $120.8 million, a 6.1% decrease year-over-year. The company experienced a net loss from continuing operations of $8.8 million, but adjusted EBITDA from continuing operations was $21.7 million. Improved performance in Pain Treatments and continued cost management contributed to results exceeding expectations, leading to raised full-year earnings guidance.

Bioventus reported net sales of $137.1 million, a decrease of 2.3% year-over-year. Net loss from continuing operations was $4.7 million, and adjusted EBITDA increased 26.1% to $28.2 million. The company also closed the sale of its Wound Business for $31.0 million and repaid $60.3 million of debt.

Bioventus reported net sales of $119.1 million, a 1.5% increase year-over-year, with a net loss from continuing operations of $100.0 million. Adjusted EBITDA exceeded expectations at $17.0 million, compared to $7.2 million in the prior-year period.

Bioventus reported a decrease in net sales of $125.8 million, down 3.5% year-over-year, and a net loss of $44.9 million, compared to a net loss of $1.9 million in the prior-year period. The decline in sales was primarily due to a decrease in the Pain Treatments vertical, while the Surgical Solutions vertical experienced growth. The company is focused on improving execution and regaining investor confidence in 2023.

Bioventus announced it has filed a Form 12b-25 for its Q3 2022 report, requiring more time to assess a potential non-cash impairment charge between $185 million and $205 million and to resolve a revised invoice for rebate claims from a large private payer. The company's management has concluded that its internal controls related to the timely recognition of quarterly rebates were inadequate.

Bioventus reported a net sales increase of 27.8% year-over-year to $140.3 million in Q2 2022. The company's net loss improved to ($8.0) million, and adjusted EBITDA increased to $22.9 million. The company updated its full-year 2022 financial guidance.

Bioventus reported a strong start to the year with a 43.4% increase in net sales compared to the previous year. The company's commercial organization performed well, and integration plans progressed. However, the company experienced a net loss of $14.8 million, compared to a net income of $24.5 million in the prior-year period, and a decrease in Adjusted EBITDA to $7.1 million from $11.1 million in the prior-year period.

Bioventus reported a net sales increase of 32.3% year-over-year to $130.4 million in Q4 2021, driven by acquisitions. However, the company experienced a net loss of $1.9 million, compared to a net income of $2.3 million in the prior year. Adjusted EBITDA increased slightly to $28.5 million from $28.2 million in the prior year.

Bioventus reported net sales of $108.9 million, a 26.8% increase year-over-year, driven by acquisitions, strong commercial execution, and recovery from the COVID-19 pandemic. However, the company experienced a net loss of ($2.3) million, compared to a net income of $8.0 million in the prior year. The company updated its full-year net sales guidance to $425-$430 million.

Bioventus reported strong second quarter results with net sales of $109.8 million, up 89.3% year-over-year. The company updated its full year 2021 financial guidance, reaffirming net sales growth guidance of 26% to 29% year-over-year and raising Non-GAAP guidance. Recent acquisitions of Bioness and Misonix raise the Total Addressable Market to $15 billion.

Bioventus Inc. reported a 4.0% increase in net sales, a 133.9% increase in net income, and completed the acquisition of Bioness. They also raised full year 2021 revenue guidance by $4 million.

Bioventus Inc. reported Q4 2020 net sales of $98.6 million, a 1% increase year-over-year. The company's net income from continuing operations was $2.3 million. Adjusted EBITDA was $28.2 million, down 8% year-over-year.